MACC1 INVOLVED IN THE REGULATION OF RESISTANCE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE GASTRIC CANCER CELLS TO TRASTUZUMAB

被引:0
|
作者
Zhang, Guofei [1 ]
Hu, Kefu [1 ]
Yu, Rong [1 ]
Su, Gang [1 ]
Xiong, Xin [1 ]
Hu, Daqian [1 ]
Zhang, Zhihong [1 ]
机构
[1] Gongan Cty Peoples Hosp, Dept Oncol, Shizikou Town, Gongan County, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2019年 / 35卷 / 05期
关键词
MACC1; gene; human HER2-positive gastric cells; trastuzumab; resistance; POOR-PROGNOSIS; EXPRESSION; LONG;
D O I
10.19193/0393-6384_2019_5_381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to analyze whether the mechanism of the MACC1 gene involved in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells regulates trastuzumab-resistant gastric cancer. Methods: Cell lines sensitive to trastuzumab and positive for MACC1 and HER2 expression were screened from human gastric cancer cell lines, drug-resistant cell MKN45/TR was established by a stepwise dose-increase method, and the expression level o f MACC1 protein in trastuzumab-resistant cells was detected using Western blot. The inhibition rate of cell proliferation after trastuzumab treatment for 72 hours was detected using MTT. Results: Drug-resistant cell MKN45/TR was established using a stepwise dose-increase method. Half-maximal inhibitory concentration and resistance index of cell trastuzumab were detected during the induction period .The induction time was five months and the final induction concentration was 2,500 mu g/mL. Additionally, the half-maximal inhibitory concentration of trastuzumab was 295.15 mu g/mL and the drug resistance index was 9.67. Western blot detection results showed that, as compared with cells without drug resistance, the MACC1 protein level of trastuzumab-resistant cells obviously increased. NCI-N87/TR and MKN45/TR were given transinfection using MACC1 interference and empty vector and were treated using different concentrations of trastuzumab. The cell inhibition rate was detected using the MTT method. Under the function of trastuzumab at concentrations of 20 mu g/mL, 80 mu g/mL, and 160 mu g/mL, there was statistical significance between the interference group and the control group with respect to the inhibition rate of cell proliferation (P<0.05). Conclusion: MACC1 participates in the regulation of trastuzumab in gastric cancer cells. The expression level of MACC1 protein cells in transinfection resistance increases, thus interfering MACC1 in resistance cells and reversing the resistance of MACC1.
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [41] BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer
    Li, Shu-Liang
    Wang, Pei-Yao
    Jia, Yang-Pu
    Zhang, Zhao-Xiong
    He, Hao-Yu
    Chen, Peng-Yu
    Liu, Xin
    Liu, Bang
    Lu, Li
    Fu, Wei-Hua
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (11)
  • [42] A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer
    Arigami, Takaaki
    Matsushita, Daisuke
    Okubo, Keishi
    Shimonosono, Masataka
    Sasaki, Ken
    Tsuruda, Yusuke
    Kita, Yoshiaki
    Tanabe, Kan
    Mori, Shinichiro
    Yanagita, Shigehiro
    Uenosono, Yoshikazu
    Nakajo, Akihiro
    Kurahara, Hiroshi
    Ohtsuka, Takao
    SURGERY TODAY, 2022, 52 (12) : 1721 - 1730
  • [43] A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer
    Takaaki Arigami
    Daisuke Matsushita
    Keishi Okubo
    Masataka Shimonosono
    Ken Sasaki
    Yusuke Tsuruda
    Yoshiaki Kita
    Kan Tanabe
    Shinichiro Mori
    Shigehiro Yanagita
    Yoshikazu Uenosono
    Akihiro Nakajo
    Hiroshi Kurahara
    Takao Ohtsuka
    Surgery Today, 2022, 52 : 1721 - 1730
  • [44] MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer
    Badr, Marwa
    Said, Hebatallah
    Louka, Manal L.
    Elghazaly, Hesham A.
    Gaballah, Ahmed
    Abd El Mageed, Mai Atef
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (03) : 3459 - 3466
  • [45] Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis
    Shen, Kai
    Ma, Xuelei
    Zhu, Chenjing
    Wu, Xin
    Jia, Hongyuan
    SCIENTIFIC REPORTS, 2016, 6
  • [46] Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
    Fang, Yan
    Wang, Zheng
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Zhu, Li
    Chen, Weiguo
    Li, Yafen
    Chen, Xiaosong
    Shen, Kunwei
    JOURNAL OF CANCER, 2020, 11 (09): : 2602 - 2609
  • [47] Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Perik, Patrick J.
    Lub-De Hooge, Marjolijn N.
    Gietema, Jourik A.
    van der Graaf, Winette T. A.
    de Korte, M. Alexander
    Jonkman, Sharon
    Kosterink, Jos G. W.
    van Veldhuisen, Dirk J.
    Sleijfer, Dirk T.
    Jager, Pieter L.
    de Vries, Elisabeth G. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2276 - 2282
  • [48] Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Wolff, Antonio C.
    Tung, Nadine M.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2189 - +
  • [49] Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
    Hurley, J
    Doliny, P
    Reis, I
    Silva, O
    Gomez-Fernandez, C
    Velez, P
    Pauletti, G
    Pegram, MD
    Slamon, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1831 - 1838
  • [50] Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer
    Kim, Miriam
    Agarwal, Surbhi
    Tripathy, Debu
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (01) : 27 - 33